Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism
- PMID: 21095568
- PMCID: PMC3021381
- DOI: 10.1016/j.chembiol.2010.10.013
Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism
Abstract
Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Figures


Similar articles
-
Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.Biochemistry. 2013 Dec 23;52(51):9329-38. doi: 10.1021/bi4014209. Epub 2013 Nov 27. Biochemistry. 2013. PMID: 24266403 Free PMC article.
-
Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.Nucleic Acid Ther. 2014 Jun;24(3):199-209. doi: 10.1089/nat.2013.0476. Epub 2014 Apr 2. Nucleic Acid Ther. 2014. PMID: 24694346 Free PMC article.
-
Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway.Nucleic Acids Res. 2012 Dec;40(22):11270-80. doi: 10.1093/nar/gks907. Epub 2012 Oct 4. Nucleic Acids Res. 2012. PMID: 23042244 Free PMC article.
-
An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.Biomed Pharmacother. 2024 Nov;180:117557. doi: 10.1016/j.biopha.2024.117557. Epub 2024 Oct 13. Biomed Pharmacother. 2024. PMID: 39405896 Review.
-
Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Biochem Soc Trans. 2009. PMID: 19909260 Review.
Cited by
-
Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.Biochemistry. 2013 Dec 23;52(51):9329-38. doi: 10.1021/bi4014209. Epub 2013 Nov 27. Biochemistry. 2013. PMID: 24266403 Free PMC article.
-
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target.Nucleic Acids Res. 2012 Jan;40(1):11-26. doi: 10.1093/nar/gkr729. Epub 2011 Sep 9. Nucleic Acids Res. 2012. PMID: 21908410 Free PMC article. Review.
-
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600. doi: 10.1093/nar/gkx1239. Nucleic Acids Res. 2018. PMID: 29240946 Free PMC article. Review.
-
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.Cell. 2012 Aug 31;150(5):895-908. doi: 10.1016/j.cell.2012.08.002. Cell. 2012. PMID: 22939619 Free PMC article.
-
Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.Mol Ther Nucleic Acids. 2017 Sep 15;8:158-168. doi: 10.1016/j.omtn.2017.06.012. Epub 2017 Jun 21. Mol Ther Nucleic Acids. 2017. PMID: 28918018 Free PMC article.
References
-
- De Souza EB, Cload ST, Pendergrast PS, Sah DW. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology. 2009;34:142–158. - PubMed
-
- Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, Deglon N. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol. 2009;65:276–285. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources